Drugs / NSC001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06995573 | Aug 2025 → Jul 2026 overdue | Alzheimer disease | NSC-Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NSC001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06995573 ↗ |
| Action | Activate | “rigid cholinergic agonist” NCT06995573 ↗ |
| Modality | Small molecule | “orally administered small molecule” NCT06995573 ↗ |
| Route | Oral | “orally administered” NCT06995573 ↗ |